Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia

International Journal of Oncology

Volumn 31, Issue 1, 2007, Pages 153-160

  Uggla, Bertil ^a,e   Tina, Elisabet ^a   Nahi, Hareth ^b,e   Paul, Christer ^b,e   Höglund, Martin ^c   Sirsjö, Allan ^d   Tidefelt, Ulf ^a,d  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d ÖREBRO UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute leukaemia; Drug resistance; Flow cytometry; Prognosis; Reverse transcriptase polymerase chain reaction; Topoisomerase II

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; ETOPOSIDE; MESSENGER RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLOOD CELL; BONE MARROW CELL; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; PATHOLOGY; PROGNOSIS;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BLOOD CELLS; BONE MARROW CELLS; CELL SURVIVAL; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER;

EID: 34548571944     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.1.153     Document Type: Article

References (28)

1. McKenna SL and Padua RA: Multidrug resistance in leukaemia. Br J Haematol 96: 659-674, 1997.
2. Sonneveld P and List AF: Chemotherapy resistance in acute myeloid leukaemia. Best Pract Res Clin Haematol 14: 211-233, 2001.
3. Wang JC: DNA topoisomerases. Annu Rev Biochem 65: 635-692, 1996.
4. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK and Drake FH: Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 2: 209-214, 1991.
5. Woessner RD, Chung TD, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH and Johnson RK: Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res 50: 2901-2908, 1990.
6. Tanoguchi K, Sasano H, Yabuki N, Kikuchi A, Ito K, Sato S and Yajima A: Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. Mod Pathol 11: 186-193, 1998.
7. Uggla B, Mollgard L, Stahl E, Mossberg L, Karlsson MG, Paul C and Tidefelt U: Expression of topoisomerase II alpha in the G0/G1 cell cycle phase of fresh leukemic cells. Leuk Res 25: 961-966, 2001.
8. Villman K, Ståhl E, Liljegren G, Tidefelt U and Karlsson MG: Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas. Mod Pathol 15: 486-491, 2002.
9. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
10. Nitiss JL and Beck WT: Antitopoisomerase drug action and resistance. Eur J Cancer 32A: 958-966, 1996.
11. Gewirtz D: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracyline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999.
12. Deffie AM, Batra JK and Goldenberg GJ: Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62, 1989.
13. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JR and Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595, 1991.
14. Webb CD, Latham MD, Lock RB and Sullivan DM: Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51: 6543-6549, 1991.
15. Ritke MK and Yalowich JC: Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 46: 2007-2020, 1993.
16. Eijdems EW, Borst P, Jongsma AP, De Jong S, De Vries EG, van Groenigen M, Versantvoort CH, Nieuwint AW and Baas F: Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc Natl Acad Sci USA 89: 3498-3502, 1992.
17. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH and Goldenberg GJ: Relationship of DNA topoisomerase II alpha and beta expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 55: 78-82, 1995.
18. McKenna SL, West RR, Whittaker JA, Padua RA and Holmes JA: Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 8: 1498-1502, 1994.
19. Galmarini CM, Thomas X, Calvo F, Rousselot P, Jafaari AE, Cros E and Dumontet C: Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26: 621-629, 2002. (Pubitemid 34465699)
20. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K and Burke PJ: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83: 517-530, 1994.
21. Lohri A, van Hille B, Bacchi M, Fopp M, Joncourt F, Reuter J, Cerny T, Fey MF and Herrmann R: Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). Eur J Haematol 59: 206-215, 1997.
22. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R and Burnett A: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92: 2322-2333, 1998.
23. Mollgard L, Tidefelt U, Sundman-Engberg B, Lofgren C and Paul C: In vitro chemosensitivity testing in acute non-lymphocytic leukemia using the bioluminescence ATP assay. Leuk Res 24: 445-452, 2000.
24. Lohri A, van Hille B, Reuter J, Tichelli A and Herrmann R: mRNA expression, measured by quantitative reverse transcriptase polymerase chain reaction, of five putative drug resistance parameters, in normal and leukaemic peripheral blood and bone marrow. Acta Haematol 98: 1-7, 1997.
25. Ishida R, Takashima R, Koujin T, Shibata M, Nozaki N, Seto M, Mori H, Haraguchi T and Hiraoka Y: Mitotic specific phosphorylation of serine-1212 in human DNA topoisomerase IIalpha. Cell Struct Funct 26: 215-226, 2001.
26. Wells NJ, Fry AM, Guano F, Norbury C and Hickson ID: Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C. J Biol Chem 270: 28357-28363, 1995.
27. Chikamori K, Grabowski DR, Kinter M, et al: Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 278: 12696-12702, 2003.
28. Lee CG, Hague LK, Li H and Donnelly R: Identification of toposome, a novel multisubunit complex containing topoisomerase II alpha. Cell Cycle 3: 638-647, 2004.